# US 2001/0027192 A1 · Formulation comprising antibacterial substance and antiulcer substance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0027192 A1
- Document ID: US20010027192A1
- Status: Published application
- Kind: A1
- Application number: 09/858,655
- Filed: 2001-05-17
- Published: 2001-10-04
- Earliest claimed: 1993-09-09
- Inventors: Yohko Akiyama; Masafumi Nakao; Naoki Nagahara; Susumu Iwasa
- Web page: https://patentgrep.com/patent/US20010027192A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5078: {with drug-free core}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention includes a formulation which comprises an antibacterial substance and an antiulcer substance, wherein at least either of them is formulated into a gastrointestinal mucosa-adherent solid preparation. The formulation of the present invention shows long retention time in the gastrointestinal tract because of adhesion to the gastrointestinal tract mucosa, synergetically enhances the pharmaceutical effects of an antibacterial substance, specially antibiotic against Helicobacter pylori (HP) and an antiulcer substance, with very low doses of active ingredients, particularly the anti-HP antibiotic with low prevalence of side effects. The present agent is useful as an antiulcer agent, showing potent anti-HP activity.

## Claims

### Claim 1

A formulation which comprises an antibacterial substance and an antiulcer substance, wherein at least one of them is formulated into a gastrointestinal mucosa-adherent solid preparation.

### Claim 2 (depends on 1)

The formulation according to claim 1, wherein the antibacterial substance is an antibacterial substance against Helicobacter pylori.

### Claim 3 (depends on 1)

The formulation according to claim 1, wherein the gastrointestinal mucosa-adherent solid preparation further comprises a matrix containing a polyglycerin fatty acid ester.

### Claim 4 (depends on 1)

The formulation according to claim 1, wherein the gastrointestinal mucosa-adherent solid preparation contains the antibacterial substance.

### Claim 5 (depends on 1)

The formulation according to claim 1, wherein the antibacterial substance is a penicillin.

### Claim 6 (depends on 1)

The formulation according to claim 1, wherein the antibacterial substance is a macrolide antibiotic.

### Claim 7 (depends on 5)

The formulation according to claim 5, wherein the penicillin is amoxicillin.

### Claim 8 (depends on 1)

The formulation according to claim 1, wherein the antiulcer substance is a proton pump inhibitor.

### Claim 9 (depends on 8)

The formulation according to claim 8, wherein the proton pump inhibitor is a compound represented by the formula: 5
wherein ring A may optionally be substituted, R1, R3 and R4 are, the same or different, hydrogen, or an alkyl or alkoxy group, R2 is a hydrocarbon group which may optionally be substituted, and n is 0 or 1, or a salt thereof.

### Claim 10 (depends on 3)

The formulation according to claim 3, wherein the gastrointestinal mucosa-adherent solid preparation comprises a viscogenic agent capable of developing viscosity on contact with water.

### Claim 11 (depends on 10)

The formulation according to claim 10, wherein the viscogenic agent is dispersed in the gastrointestinal mucosa-adherent solid preparation.

### Claim 12 (depends on 10)

The formulation according to claim 10, wherein the viscogenic agent coats the gastrointestinal mucosa-adherent solid preparation.

### Claim 13 (depends on 10)

The formulation according to claim 10, wherein the viscogenic agent is an acrylic acid polymer or its salt.

### Claim 14

A set for the use in treating a gastrointestinal ulcer in mammals which comprises (1) an antibacterial substance and a pharmaceutically acceptable carrier thereof, and (2) an antiulcer substance and a pharmaceutically acceptable carrier thereof, wherein at least one of the substances is formulated into a gastrointestinal mucosa-adherent solid preparation.

### Claim 15

A method of treating a gastrointestinal ulcer in mammals which comprises administering to the mammals a therapeutically effective amount of an antibacterial substance and a therapeutically effective amount of an antiulcer substance.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the antibacterial substance and the antiulcer substance are administered simutaneously.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the antibacterial substance and the antiulcer substance are administered sequentially.
